Last reviewed · How we verify

Bupivacaine indwelling catheter

Denver Health and Hospital Authority · FDA-approved active Small molecule

Bupivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce local anesthesia.

Bupivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce local anesthesia. Used for Local anesthesia via indwelling catheter for perioperative pain management, Regional anesthesia for surgical procedures.

At a glance

Generic nameBupivacaine indwelling catheter
Also known asOnQ pain pump, Continuous infusion of bupivacaine
SponsorDenver Health and Hospital Authority
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine reversibly binds to and blocks voltage-gated sodium channels on the inner surface of nerve cell membranes, preventing depolarization and nerve impulse transmission. When delivered via an indwelling catheter, it provides continuous or intermittent local anesthetic effect at the catheter site or surrounding tissue. This allows for prolonged regional anesthesia or analgesia without systemic administration.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: